Thyrocare Technologies Latest Share Price (THYROCARE)
TODAY IN ONE LINE
THYROCARE rose 2.1% on light volume, outperforming Nifty's -0.4% move, supported by recent strong earnings.
With a market cap of ₹9,471.93 Cr., it trades at a P/E of 52.89. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Thyrocare Technologies flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 116.3% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 24.3% and Profit up 34.1%
- ●High Capital EfficiencyROCE of 35.4% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 28.4%
- ●Healthy Operating MarginsOPM is structurally strong at 32.1%
- ●High Promoter HoldingPromoters hold 60.9% skin-in-the-game
- ●Steady Dividend YieldReliable 1.50% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.09x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 53.1x
- ●Rising Receivables vs SalesReceivables grew 58.4% outpacing sales growth of 20.2%
- ●Promoter Pledging DetectedPledge activity recorded on 18-Sep-2025 19:15
Latest Thyrocare Technologies News
What changed recently?
Recent events, corporate actions, and announcements.
Thyrocare Technologies Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Thyrocare Technologies Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Thyrocare Technologies Ltd trades at a P/E of 52.89× and P/B of 15.93×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Thyrocare Technologies Ltd technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Thyrocare Technologies Ltd — derived from the latest tape, not yesterday's close.
Thyrocare Technologies Ltd last traded at ₹596.2 with an intraday range of ₹583–₹598.85 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹596.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 634.07 | +37.87 | +6.35% |
| R3 | 618.22 | +22.02 | +3.69% |
| R2 | 608.53 | +12.33 | +2.07% |
| R1 | 602.37 | +6.17 | +1.03% |
| PIVOT | 592.68 | -3.52 | -0.59% |
| CURRENT | 596.20 | — | — |
| S1 | 586.52 | -9.68 | -1.62% |
| S2 | 576.83 | -19.37 | -3.25% |
| S3 | 570.67 | -25.53 | -4.28% |
| S4 | 554.82 | -41.38 | -6.94% |
THYROCARE is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹583–₹595
Trading Above opening range, showing Bullishness
Thyrocare Technologies Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Thyrocare Technologies Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
Thyrocare Technologies Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹9,471.93 Cr. and reported EPS of ₹11.10.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 687 | 829 ▲ 20.6% |
| Sales Growth YoY %Derived | 20.19% | 20.61% |
| Other Income | 15 | 17 ▲ 14.6% |
| Total Income | 702 | 846 ▲ 20.5% |
| 191 | 220 ▲ 14.9% | |
| Gross ProfitDerived | 496 | 609 ▲ 22.8% |
| Gross Margin %Derived | 72.20% | 73.52% |
| 306 | 347 ▲ 13.6% | |
| EBITDA (Operating Profit)Derived | 190 | 262 ▲ 37.7% |
| OPM %Derived | 27.69% | 31.61% |
| 58 | 55 ▼ 5.3% | |
| Profit Before Tax (PBT) | 147 | 211 ▲ 44.0% |
| 55 | 50 ▼ 8.5% | |
| Effective Tax %Derived | 37.23% | 23.66% |
| Total Profit for Period | 91 | 163 ▲ 79.4% |
| Less: Non-controlling Interests | -1 | -0 ▲ 75.0% |
| Net Profit (Owner's PAT)Derived | 92 | 163 ▲ 78.2% |
| Net Profit Margin %Derived | 13.31% | 19.67% |
| PAT Growth YoY %Derived | 29.32% | 78.17% |
| Earnings Per Share (EPS ₹) | 5.76 | 10.24 ▲ 77.8% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.1% |
| Share of Profit from Associates/JVs | -1 | 1 ▲ 196.5% |
| Other Comprehensive Income (Net of Tax) | -1 | 0 ▲ 149.4% |
| Total Expenses (incl. D&A & Interest) | 555 | 635 ▲ 14.3% |
| Material Cost % of RevenueDerived | 27.39% | 26.38% |
| Employee Cost % of RevenueDerived | 18.44% | 16.65% |
| Other Cost % of RevenueDerived | 26.06% | 25.25% |
| Interest Coverage (x)Derived | 44.30x | 72.66x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 403 | 433 ▲ 7.5% | 495 ▲ 14.2% | 589 ▲ 19.1% | 527 ▼ 10.6% | 572 ▲ 8.6% | 687 ▲ 20.2% | 829 ▲ 20.6% | |
| Sales Growth YoY %Derived | — | 7.52% | 14.18% | 19.05% | -10.56% | 8.58% | 20.19% | 20.61% | |
| Other Income | 10 | 8 ▼ 22.3% | 12 ▲ 60.8% | 29 ▲ 135.3% | 8 ▼ 71.2% | 9 ▲ 11.3% | 15 ▲ 58.3% | 17 ▲ 14.6% | |
| Total Income | 413 | 441 ▲ 6.8% | 507 ▲ 15.0% | 618 ▲ 21.9% | 535 ▼ 13.4% | 581 ▲ 8.6% | 702 ▲ 20.8% | 846 ▲ 20.5% | |
111 | 117 ▲ 5.9% | 164 ▲ 40.0% | 170 ▲ 3.5% | 163 ▼ 3.8% | 167 ▲ 2.1% | 191 ▲ 14.6% | 220 ▲ 14.9% | ||
| Gross ProfitDerived | 292 | 316 ▲ 8.1% | 331 ▲ 4.6% | 419 ▲ 26.7% | 363 ▼ 13.3% | 405 ▲ 11.5% | 496 ▲ 22.5% | 609 ▲ 22.8% | |
| Gross Margin %Derived | 72.57% | 72.97% | 66.86% | 71.18% | 69.01% | 70.85% | 72.20% | 73.52% | |
138 | 144 ▲ 3.9% | 159 ▲ 11.1% | 184 ▲ 15.6% | 243 ▲ 32.1% | 268 ▲ 10.0% | 306 ▲ 14.3% | 347 ▲ 13.6% | ||
| EBITDA (Operating Profit)Derived | 154 | 173 ▲ 11.9% | 171 ▼ 0.7% | 235 ▲ 37.2% | 120 ▼ 48.9% | 137 ▲ 14.5% | 190 ▲ 38.5% | 262 ▲ 37.7% | |
| OPM %Derived | 38.28% | 39.82% | 34.62% | 39.89% | 22.79% | 24.03% | 27.69% | 31.61% | |
27 | 27 ▲ 1.5% | 31 ▲ 14.6% | 36 ▲ 16.3% | 41 ▲ 13.3% | 51 ▲ 24.7% | 58 ▲ 13.9% | 55 ▼ 5.3% | ||
| Profit Before Tax (PBT) | 137 | 140 ▲ 1.8% | 153 ▲ 9.0% | 228 ▲ 49.4% | 87 ▼ 61.6% | 96 ▲ 9.4% | 147 ▲ 53.7% | 211 ▲ 44.0% | |
53 | 52 ▼ 1.7% | 39 ▼ 24.4% | 52 ▲ 31.2% | 24 ▼ 53.0% | 26 ▲ 9.3% | 55 ▲ 106.5% | 50 ▼ 8.5% | ||
| Effective Tax %Derived | 38.52% | 37.17% | 25.78% | 22.63% | 27.72% | 27.71% | 37.23% | 23.66% | |
| Total Profit for Period | 85 | 88 ▲ 3.8% | 113 ▲ 28.0% | 176 ▲ 55.7% | 64 ▼ 63.5% | 69 ▲ 8.0% | 91 ▲ 30.6% | 163 ▲ 79.4% | |
| Less: Non-controlling Interests | — | — | — | — | -0 | -1 ▼ 876.9% | -1 ▲ 40.2% | -0 ▲ 75.0% | |
| Net Profit (Owner's PAT)Derived | 85 | 88 ▲ 3.8% | 113 ▲ 28.0% | 176 ▲ 55.7% | 64 ▼ 63.4% | 71 ▲ 9.7% | 92 ▲ 29.3% | 163 ▲ 78.2% | |
| Net Profit Margin %Derived | 21.13% | 20.41% | 22.87% | 29.91% | 12.24% | 12.37% | 13.31% | 19.67% | |
| PAT Growth YoY %Derived | — | 3.84% | 27.97% | 55.68% | -63.39% | 9.72% | 29.32% | 78.17% | |
| Earnings Per Share (EPS ₹) | 5.38 | 5.58 ▲ 3.7% | 7.13 ▲ 27.8% | 11.10 ▲ 55.7% | 4.06 ▼ 63.4% | 4.45 ▲ 9.6% | 5.76 ▲ 29.4% | 10.24 ▲ 77.8% | |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.1% | 16 ▲ 0.1% | 16 ▲ 0.1% | 16 ▲ 0.1% | 16 ▲ 0.0% | 16 ▲ 0.1% | 16 ▲ 0.1% | |
| Share of Profit from Associates/JVs | 1 | 1 ▼ 22.7% | -0 ▼ 113.7% | -0 ▼ 157.1% | 1 ▲ 755.6% | 0 ▼ 66.9% | -1 ▼ 469.2% | 1 ▲ 196.5% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 9.1% | -1 ▼ 1258.3% | -0 ▲ 94.2% | 2 ▲ 2012.5% | 0 ▼ 81.0% | -1 ▼ 365.5% | 0 ▲ 149.4% | |
| Total Expenses (incl. D&A & Interest) | 275 | 301 ▲ 9.3% | 355 ▲ 17.8% | 390 ▲ 10.1% | 448 ▲ 14.7% | 486 ▲ 8.5% | 555 ▲ 14.3% | 635 ▲ 14.3% | |
| Material Cost % of RevenueDerived | 26.92% | 26.53% | 32.86% | 28.23% | 29.79% | 28.77% | 27.39% | 26.38% | |
| Employee Cost % of RevenueDerived | 10.76% | 11.29% | 11.74% | 10.38% | 20.15% | 18.86% | 18.44% | 16.65% | |
| Other Cost % of RevenueDerived | 23.53% | 21.85% | 20.50% | 20.91% | 26.06% | 27.96% | 26.06% | 25.25% | |
| Interest Coverage (x)Derived | 209.93x | 76.01x | 162.03x | 84.82x | 34.61x | 21.53x | 44.30x | 72.66x |
Thyrocare Technologies segment analysis : revenue and profit mix.
Disclosed business segments at Thyrocare Technologies with their share of revenue and profit, switchable between consolidated and standalone reporting.
Thyrocare Technologies discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Thyrocare Technologies Ltd.
Our AI distills the core fundamental drivers supporting Thyrocare Technologies Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Thyrocare Technologies Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 118.6% YoY, reflecting exceptional earnings acceleration momentum.
ROCE 35.40% significantly exceeds industry median, indicating superior capital productivity.
Operating margin 24.90% demonstrates exceptional cost efficiency and profitability strength.
Debt-to-equity 0.0009x ensures fortress balance sheet with minimal leverage risk.
Promoter holding 60.9% provides stable long-term ownership and strategic alignment.
Key Risks.
P/E ratio 53.13x raises valuation concerns relative to near-term growth expectations.
Payout ratio 159.63% signals unsustainable dividend policy exceeding net income.
FII holdings eased from 12.82% to 4.85%, signaling foreign investor confidence erosion.
Public shareholding 10.61% remains limited, potentially constraining trading liquidity.
Negative investing cash flow indicates capex-heavy operations straining cash generation.
Flip Conditions.
Valuation risk. a P/E above 69 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 23% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.75%.
Thyrocare Technologies Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Thyrocare Technologies Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Thyrocare Technologies Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Thyrocare Technologies Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Thyrocare Technologies Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Thyrocare Technologies Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Thyrocare Technologies Ltd stood at 50.1% of traded volume, against a 20-day average of 50.4%.
Thyrocare Technologies announcements: results, concalls, ratings, M&A.
Filings Thyrocare Technologies sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Thyrocare Technologies files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 133 documents below.
General Updates
Thyrocare Technologies Limited has informed the Exchange regarding complete discharge and release of Transaction Documents pursuant to full…
Disclosure under SEBI Takeover Regulations
Thyrocare Technologies Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Disclosure under SEBI Takeover Regulations
Docon Technologies Private Ltd has submitted to the Exchange a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Updates
Thyrocare Technologies Limited has informed the Exchange regarding 'Communication Received From Promoter Regarding Release Of Pledge On Equity Shares…
Updates
Thyrocare Technologies Limited has informed the Exchange regarding communication received from Promoter regarding sale of 1,57,69,696 Equity Shares…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Thyrocare Technologies dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Thyrocare Technologies has declared, sequenced by announce and record date.
Thyrocare Technologies corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Thyrocare Technologies insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Thyrocare Technologies as reported to SEBI — buying and selling signals from the people who know the business best.
Thyrocare Technologies insider activity below tracks 44 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
About Thyrocare Technologies Ltd: business, sector, key facts.
What Thyrocare Technologies Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Thyrocare Technologies Ltd operates in the Healthcare Service Provider industry under the Healthcare sector, listed as NSE: THYROCARE, BSE: 539871.
Thyrocare Technologies Limited is a prominent Indian healthcare company specializing in diagnostic testing services. Its primary business revolves around providing a wide range of medical tests to patients, hospitals, and other laboratories across the country. The company’s focus is on early detection and proactive management of various health conditions, contributing to preventative healthcare.
Thyrocare's services encompass a broad spectrum of diagnostic tests, targeting numerous health areas. These include thyroid disorders (the company's namesake), growth and metabolic issues, autoimmune diseases, diabetes, anemia, cardiovascular health concerns, infertility, and a variety of infectious diseases. This comprehensive approach allows for a holistic assessment of patient health, aiding in early diagnosis and subsequent treatment.
The company operates under a three-segment structure: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment forms the core of Thyrocare's business, encompassing the vast majority of its testing portfolio. The Imaging Services segment likely includes diagnostic imaging procedures, although the provided text does not offer specifics. The "Others" segment appears to encompass ancillary products and services, such as the sale of glucometers and glucostrips under the Sugarscan brand, as well as consumables and radiopharmaceutical products.
A significant aspect of Thyrocare's strategy is its Aarogyam brand. This brand offers a suite of wellness and preventive healthcare tests, catering to individuals focused on proactive health maintenance. These profiles of tests are designed to identify potential health risks early on, allowing for timely intervention and improved health outcomes. By offering a range of tests, from specialized diagnostic tests to comprehensive wellness packages, Thyrocare aims to cater to a wide patient base and various healthcare needs.
In summary, Thyrocare Technologies Limited is a vertically integrated diagnostics company focused on providing a comprehensive suite of testing services aimed at early disease detection and preventive healthcare. Its diverse offerings, including specialized tests, wellness packages, and ancillary products, position it as a major player in the Indian healthcare market. The company's success hinges on its ability to deliver accurate, timely, and cost-effective diagnostic services across a broad range of health conditions.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Health X Platform (HEALTHX) Share PricePeer
- Krsnaa Diagnostics (KRSNAA) Share PricePeer
- Dr Lal Path Labs (LALPATHLAB) Share PricePeer
- Metropolis Healthcare (METROPOLIS) Share PricePeer
- Suraksha Diagnostic (SURAKSHA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Thyrocare Technologies Ltd (THYROCARE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Thyrocare Technologies Ltd (THYROCARE)?
The current share price of Thyrocare Technologies Ltd (THYROCARE) is ₹596.20. Today, the stock has gained by ₹12.20 (2.09%), trading in a range of ₹583.00 to ₹598.85. The stock opened at ₹586.00 with a trading volume of 1,90,972 shares.
02Is Thyrocare Technologies Ltd stock a good investment for long-term?
Thyrocare Technologies Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹9,471.93 Cr., P/E ratio of 52.89, ROE of 28.4%, and ROCE of 35.4%. The dividend yield stands at 1.5%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Thyrocare Technologies Ltd stock?
The 52-week high price of Thyrocare Technologies Ltd (THYROCARE) is ₹1,610.00, while the 52-week low is ₹342.55. Currently trading at ₹596.20, the stock is 74.05% above its 52-week low and 62.97% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Thyrocare Technologies Ltd stock at the current price?
Whether to buy Thyrocare Technologies Ltd stock at ₹596.20 depends on multiple factors. The stock is currently trading with a P/E ratio of 52.89 and P/B ratio of 15.93. Today's performance shows a gain of 2.09%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Thyrocare Technologies Ltd and when is the next dividend?
Thyrocare Technologies Ltd offers a dividend yield of 1.5%, which means for every ₹100 invested at the current price of ₹596.20, you can expect to receive approximately ₹1.50 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd's key financial metrics include: P/E Ratio: 52.89, P/B Ratio: 15.93, ROE: 28.4%, ROCE: 35.4%, Dividend Yield: 1.5%, EPS: ₹11.10, Book Value: ₹36.80, and Debt-to-Equity: 0.09. The company's market cap stands at ₹9,471.93 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Thyrocare Technologies Ltd stock performing today in the market?
Thyrocare Technologies Ltd stock opened at ₹586.00 and is currently trading at ₹596.20, showing a gain of ₹12.20 (2.09%). The intraday high is ₹598.85 and low is ₹583.00. The trading volume stands at 1,90,972 shares, indicating moderate market participation today.
08What is the P/E ratio of Thyrocare Technologies Ltd and what does it indicate?
Thyrocare Technologies Ltd has a Price-to-Earnings (P/E) ratio of 52.89, which means investors are willing to pay 52.89 for every ₹1 of earnings. With an EPS of ₹11.10, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Thyrocare Technologies Ltd (THYROCARE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.